Jiangsu Hengrui Medicine's (SHA:600276) subsidiaries received the Chinese drug administration's approval to conduct clinical trials on three drugs, according to a Shanghai Stock Exchange disclosure on Wednesday.
The drugs are the SHR-A2102 injection, the adebeli monoclonal antibody injection, and the bevacizumab injection. The SHR-A2102 injection will be tested in combination with other anti-tumor treatments in patients with advanced solid tumors.
The product will be tested as a monotherapy drug for patients with advanced solid tumors, the Chinese medicine maker said.
The company's shares jumped nearly 5% in recent trade.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments